The effect of intravesical mitomycin C on the recurrence of superficial (Ta-T1) bladder cancer. A Hungarian Multicenter Study.

We evaluated the prophylactic efficacy of instillations of intravesical mitomycin C in 57 patients with primary superficial bladder cancer in a multicenter clinical trial. After complete transurethral resection of Ta-T1 G1-G2 transitional cell bladder carcinomas, patients were treated with mitomycin 40 mg/50 ml saline of 15 instillations for 12 months. Most of the complications were mild and transient but two patients dropped out of the trial because of moderate side effects. Fifty-one patients were evaluable. We observed tumour recurrences in six patients (11.8%) during a median follow-up of 44.5 months. The recurrences were treated by transurethral resection. There was no muscle invasive progression in the recurrences. Our investigations confirm the effectiveness of mitomycin C in the treatment of patients with superficial bladder cancer.

Supernumerary nipples and urologic malignancies.

The prevalence of five minor malformations and three palmar or finger crease abnormalities was determined in a total of 203 patients with urologic malignancies. An equal number of control individuals with acute infections or cardiopulmonary complaints was matched consecutively to the patients by sex and age. A significantly higher frequency of supernumerary nipples was found in all types of urologic tumors examined: the total prevalence was 32 of 203 in the patients, and four of 203 in the controls (p less than 0.001). Bifid uvula, preauricular pits, and abnormal palmar creases were also slightly more common in the patients, but the differences were not statistically significant.